Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5-FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 09 Jun 2012 Actual initiation date changed from 22 Jan 2008 to 28 Nov 2007 as reported by European Clinical Trials Database.
- 21 Feb 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.